These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3571544)

  • 1. The release and percutaneous permeation of anthralin products, using clinically involved and uninvolved psoriatic skin.
    Wang JC; Patel BG; Ehmann CW; Lowe N
    J Am Acad Dermatol; 1987 Apr; 16(4):812-21. PubMed ID: 3571544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin.
    Paramsothy Y; Lawrence CM
    Br J Dermatol; 1987 Apr; 116(4):517-9. PubMed ID: 3580286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of the expression of Bcl-2, Bcl-x, Bax, Fas, and Fas ligand in the involved skin of psoriasis vulgaris following topical anthralin therapy.
    Yamamoto T; Nishioka K
    Skin Pharmacol Appl Skin Physiol; 2003; 16(1):50-8. PubMed ID: 12566829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of steroid and dithranol therapy on cyclic nucleotides in psoriatic epidermis.
    Saihan EM; Albano J; Burton JL
    Br J Dermatol; 1980 May; 102(5):565-9. PubMed ID: 6248098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin polyamine levels in psoriasis: the effect of dithranol therapy.
    Bohlen P; Grove J; Beya MF; Koch-Weser J; Henry MH; Grosshans E
    Eur J Clin Invest; 1978 Aug; 8(4):215-8. PubMed ID: 100325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence remission spectroscopy of psoriatic lesions and the effect of topical anthralin therapy.
    Wollina U; Schmidt WD; Koch A; Scheibe A; Erfurth F; Fassler D
    J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1409-13. PubMed ID: 19508501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration studies of topical anthralin.
    Selim MM; Goldberg LH; Schaefer H; Bishop SC; Farber EM
    Br J Dermatol; 1981 Aug; 105 Suppl 20():101-3. PubMed ID: 7284253
    [No Abstract]   [Full Text] [Related]  

  • 8. Skin permeability of anthralin.
    Schalla W; Bauer E; Schaefer H
    Br J Dermatol; 1981 Aug; 105 Suppl 20():104-8. PubMed ID: 7284254
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of anthralin in skin during treatment.
    Juhlin L; Schroot B
    Acta Derm Venereol Suppl (Stockh); 1985; 120():27-9. PubMed ID: 3869415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical properties and stability of anthralin in model systems and human skin.
    Melo TS; Dubertret L; Prognon P; Gond A; Mahuzier G; Santus R
    J Invest Dermatol; 1983 Jan; 80(1):1-6. PubMed ID: 6848605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a psoriatic skin model produced with involved or uninvolved cells.
    Jean J; Leroy M; Duque-Fernandez A; Bernard G; Soucy J; Pouliot R
    J Tissue Eng Regen Med; 2015 Jul; 9(7):789-98. PubMed ID: 23281213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anthralin erythema: effect of concentration, contact time, oxidation products and corticosteroids. Clinical, reflection photometry and electron microscopy studies].
    Puschmann M
    Z Hautkr; 1983 Nov; 58(22):1646-7. PubMed ID: 6659639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The in vivo fate of topically applied dithranol in the skin of the hairless rat. A comparison of continuous and short contact application.
    Cavey D; Dickinson RG; Shroot B; Schaefer H
    Arzneimittelforschung; 1985; 35(3):605-9. PubMed ID: 4039587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug.
    Schallreuter KU; Pittelkow MR
    Arch Dermatol; 1987 Nov; 123(11):1494-8. PubMed ID: 2445297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical characterization of the stratum corneum of an in vitro psoriatic skin model by ATR-FTIR and Raman spectroscopies.
    Bernard G; Auger M; Soucy J; Pouliot R
    Biochim Biophys Acta; 2007 Sep; 1770(9):1317-23. PubMed ID: 17659842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous quantitation of 1,8,9-anthracenetriol, 1,8-dihydroxy-9,10-anthraquinone, and 1,8,1',8'-tetrahydroxy-10,10'-dianthrone by reversed-phase high-performance liquid chromatography.
    Wurster DE; Upadrashta SM
    J Chromatogr; 1986 Jul; 362(1):71-8. PubMed ID: 3745364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA replication and repair by anthralin or danthron in cultured human cells.
    Clark JM; Hanawalt PC
    J Invest Dermatol; 1982 Jul; 79(1):18-22. PubMed ID: 7086172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The irritancy of anthralin is inhibited by repeat applications of a subirritant concentration.
    Parslew R; Friedmann PS
    Br J Dermatol; 1999 Sep; 141(3):469-74. PubMed ID: 10583050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsoriatic drug action of anthralin: oxidation reactions with peroxidizing lipids.
    Ducret F; Lambelet P; Löliger J; Savoy MC
    J Free Radic Biol Med; 1985; 1(4):301-6. PubMed ID: 3836247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-psoriatic drug anthralin activates transcription factor NF-kappa B in murine keratinocytes.
    Schmidt KN; Podda M; Packer L; Baeuerle PA
    J Immunol; 1996 Jun; 156(11):4514-9. PubMed ID: 8666828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.